Dear Dr. Sturm,

I was involved in developing the immune phenotyping panels for the ONE Study (you cited these panels as a standardized approach for immune monitoring in Stem Cells International · January 2017). I would like to inform you that the ONE study panels have been modified due to some issues such as instability of the CD62L antigen, absence of exhaustion markers etc. The new version of the panels are now used for the BioDrIM study by a related / overlapping group of researchers (www.biodrim.eu). I contacted the central immune monitoring lab of the ONE study ([email protected]) who would be happy to be contacted by your team to explain the rationale behind the panel modificiations based on the lessons learned during the ONE Study. Of course, I would also be happy to answer any questions you might have.

All the best for your exciting Tx and tolerance studies !

Michael Kapinsky

Sr. Marketing Manager / Beckman Coulter Life Sciences

More Michael Kapinsky's questions See All
Similar questions and discussions